Indaptus Therapeutics
INDP
17 hedge funds and large institutions have $378K invested in Indaptus Therapeutics in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.02% less ownership
Funds ownership: 0.19% → 0.17% (-0.02%)
6% less funds holding
Funds holding: 18 → 17 (-1)
30% less capital invested
Capital invested by funds: $540K → $378K (-$162K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$35.3K |
| 2 |
IHL
Investment House LLC
Redondo Beach,
California
|
+$23.6K |
| 3 |
VF
Virtu Financial
New York
|
+$10.6K |
| 4 |
Renaissance Technologies
New York
|
+$669 |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
+$415 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$14K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.01K |
| 4 |
PVI
Pine Valley Investments
Marlton,
New Jersey
|
-$138 |
| 5 |
BSB
Bangor Savings Bank
Bangor,
Maine
|
-$23 |
INDP Hedge Fund Activity: Q1 2025 in Review
17 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q1 2025, worth a combined $378K — down 30% from $540K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of INDP and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Geode Capital Management, adding an estimated $35.3K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $15K sold.
- 17 institutional investors held Indaptus Therapeutics (INDP) as of Q1 2025, down from 18 in Q4 2024.
- Funds reported $378K of Indaptus Therapeutics stock for Q1 2025, down 30% quarter-over-quarter.
- 1 fund opened new Indaptus Therapeutics positions in Q1 2025 and 2 closed out, a net change of -1 holder.
- The largest Indaptus Therapeutics buyer in Q1 2025 was Geode Capital Management, an estimated $35.3K added.
- The largest Indaptus Therapeutics seller in Q1 2025 was Susquehanna International Group, an estimated $15K sold.
Based on aggregated 13F filings for Q1 2025.